Expression of cyclooxygenase-2 in Hodgkin's lymphoma:its role in cell proliferation and angiogenesis

References

• Smith W L, Dewitt D L, Garavito R M. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 2000; 69: 145–182
   PubMed Web of Science ®Google Scholar
• Vane J R, Bakhle Y S, Botting R M. Cyclooxygenase 1 and 2. Ann Rev Pharmcol Toxicol 1998; 38: 97–120
   PubMed Web of Science ®Google Scholar
• Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–1188
   PubMed Web of Science ®Google Scholar
• Sinicrope F A, Lemoine M, Xi L, Lynch P M, Cleary K R, Shen Y, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative sporadic cancers. Gastroenterology 1999; 117: 350–358
   PubMed Web of Science ®Google Scholar
• Joo Y -E, Kim H -S, Min S -W, Lee W -S, Park C -H, Park C -S, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002; 31: 147–154
   PubMedGoogle Scholar
• Jacoby R F, Seibert K, Cole C E, Kelloff G, Lubet R A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040–5044
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Egan K M, Hunter D J, Stampfer M J, Colditz G A, Willett W C, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–614
   PubMed Web of Science ®Google Scholar
• Schuller H M, Plummer H K, III, Bochsier P N, Dudrick P, Bell J L, Harris R E. Co-expression of β-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. Int J Oncol 2001; 19: 445–449
   PubMed Web of Science ®Google Scholar
• Half E, Tang X M, Gwyn K, Sahin A, Wathen K, Sincrope F A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62: 1676–1681
   PubMed Web of Science ®Google Scholar
• Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6: 1229–1238
   PubMed Web of Science ®Google Scholar
• Lee J S, Choi Y D, Lee J H, Nam J H, Choi C, Lee M C, et al. Expression of cyclooxygenase-2 in adenocarcinoma of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol Oncol 2004; 95: 523–529
   PubMed Web of Science ®Google Scholar
• Tilley S L, Coffman T M, Koller B H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15–23
   PubMed Web of Science ®Google Scholar
• Burke J S. Hodgkin's disease: Histopathology and differential diagnosis. Neoplastic Hematopathology2nd edn., D M Knowles. Lippincott Williams and Wilkins, Philadelphia, PA 2003; 623–665
   Google Scholar
• Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al. Hodgkin disease: Hodgkin and Reed/Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994; 91: 10962–10966
   PubMed Web of Science ®Google Scholar
• Hsu S M, Hsu P -L, Lo S -S, Wu K. Expression of prostaglandin H synthase (cyclooxygenase) in Hodgkin's mononuclear and Reed-Sternberg cells. Functional resemblance between H-RS cells and histiocytes or interdigitating cells. Am J Pathol 1988; 133: 5–12
   PubMed Web of Science ®Google Scholar
• Hazar B, Ergin M, Setrek E, Erdoğan Ş, Tuncer İ, Hankverdi S. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 2004; 45: 1395–1399
   PubMed Web of Science ®Google Scholar
• Chang E T, Zheng T, Weir E G, Borowitz M, Mann R B, Spiegelman D, et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 2004; 96: 305–315
   PubMed Web of Science ®Google Scholar
• Hsu S M, Xie S S, Hsu P -L. Cultured Reed-Sternberg cells HDLM-1 and KM-H2 can be induced to become histiocyte like cells. H-RS cells are not derived from lymphocytes. Am J Pathol 1990; 137: 353–367
   PubMed Web of Science ®Google Scholar
• Pathology and genetics of tumors of hematopoietic and lymphoid tissues. World Health Organization Classification of tumors, E S Jaffe, N L Harris, H Stein, J N Voordiman. IARC Press, Lyon 2001; 237–253
   Google Scholar
• Ogami M, Ikura Y, Nishiguchi S, Kuroki T, Ueda M, Sakurai M. Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma. Lab Invest 1999; 79: 12–26
   Google Scholar
• Cattoretti G, Becker M H, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357–363
   PubMed Web of Science ®Google Scholar
• Spina D, Leonacini L, Clos P, Megha T, Pacenti L, Tosi P, et al. Growth vs, DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells. Int J Cancer 1996; 66: 179–183
   PubMed Web of Science ®Google Scholar
• Abele M C, Valente G, Kerim S, Navone R, Onesti P, Chiusa L, et al. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 1997; 82: 281–285
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis M I, Theodossiou D, Barbatis K, O'Byrne K, Harris A L, et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res 1997; 3: 2485–2492
   PubMed Web of Science ®Google Scholar
• Norrby K, Ridell B. Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and Factor VIII. APMIS 2003; 111: 483–489
   PubMed Web of Science ®Google Scholar
• Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper M S, Jackson D G, et al. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci 2002; 99: 16069–16074
   PubMed Web of Science ®Google Scholar
• Fina L, Molgaard H V, Robertson D, Bradley N J, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417–2426
   PubMed Web of Science ®Google Scholar
• Ichinoe M, Mikami T, Shiraishi H, Okayasu I. High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth type early gastric carcinomas. Histopathology 2004; 45: 612–618
   PubMed Web of Science ®Google Scholar
• Lao M, Zhou W, Sangha S, Albert A, Chang A J, Liu T C, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005; 11: 1618–1628
   PubMed Web of Science ®Google Scholar
• Sorensen H T, Friis S, Norgard B, Mellemkajaer L, Blot W J, McLaughlin J K, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 1687–1692
   PubMed Web of Science ®Google Scholar
• Ferrara N, Houck K, Jakeman L, Leung D W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18–32
   PubMed Web of Science ®Google Scholar
• Kerbel R S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505–515
   PubMed Web of Science ®Google Scholar
• Klein R D, Van Pelt C S, Sabichi A L, dela Cerda J, Fischer S M, Fürstenberger G, et al. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 2005; 65: 1808–1813
   PubMed Web of Science ®Google Scholar
• Pai R, Szabo I L, Soreghan B A, Atay S, Kawahara H, Tarnawski A S. PGE (2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001; 286: 923–928
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostropoulou I A, Talks K L, Turley H, Dehnam P, Tan D C, Mariatos G, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677–683
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Lavine A J. Surfing the p53 network. Nature 2000; 408: 307–310
   PubMed Web of Science ®Google Scholar
• Hussain S P, Harris C C. P53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous and exogenous carcinogens to human cancer. Mut Res 1999; 428: 23–32
   PubMed Web of Science ®Google Scholar
• Rogel A, Popliker M, Webb C G, Oren M. P53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol Cell Biol 1985; 5: 2851–2855
   PubMed Web of Science ®Google Scholar
• Gupta R K, Norton A J, Thompson I W, Lister T A, Bodmer J G. P53 expression in Reed-Sternberg cells of Hodgkin disease. Br J Cancer 1992; 86: 649–652
   Web of Science ®Google Scholar
• Wang J, Taylor C R. Apoptosis and cell cycle related genes and protein in classical Hodgkin lymphoma: application of tissue microarray technique. Appl Immunohistochem Mol 2003; 11: 206–231
   PubMedGoogle Scholar
• Subbaramaiah K, Altorki N, Chung W J, Mestre J R, Sampat A, Dannenberg A J. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274: 10911–10915
   PubMed Web of Science ®Google Scholar
• Yu H -P, Xu S -Q, Liu L, Shi L -Y, Cai X -K, Lu W -H, et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of esophagus. Cancer Lett 2003; 198: 193–201
   PubMed Web of Science ®Google Scholar
• Gallo O, Schiavone N, Papucci L, Sardi I, Magnelli L, Franchi A, et al. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol 2003; 163: 723–732
   PubMed Web of Science ®Google Scholar
• Shariat S F, Matsumoto K, Kim J -H, Ayala G E, Zhou J -H, Jian W, et al. Correlation of cyclooxygenase-2 expression with molecular markers. Pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 2003; 169: 938–942
   PubMed Web of Science ®Google Scholar
• Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 2003; 22: 99–105
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Roers A, Küppers R, Rajewsky K, Hansmann M -L. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 1999; 94: 1755–1760
   PubMed Web of Science ®Google Scholar
• Moggio E M, Stekelenburg E, Van den Berg A, Poppema S. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int J Cancer 2001; 94: 60–66
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger L R, Yunis J, Nowell P C, Croce C M. Cloning the chromosome break-point of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097–1099
   PubMed Web of Science ®Google Scholar
• Hell K, Lorenzen J, Fischer R, Hansmann M L. Hodgkin cells accumulate mRNA for bcl-2. Lab Invest 1995; 73: 492–496
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, Viviani S, Bonfante V, Nadali G, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classic Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002; 100: 3935–3941
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow J D, Beauchamp R D, DuBois R N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362–366
   PubMed Web of Science ®Google Scholar
• Sun Y, Tang X M, Half E, Kuo M T, Sinicrope F A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002; 62: 6323–6328
   PubMed Web of Science ®Google Scholar
• Honjo S, Osaki M, Ardyanto T D, Hiramatsu T, Maeta N, Ito H. COX-2 inhibitor, NS398, enhances via modulation of PTEN-Akt pathway in human gastric carcinoma cell line. DNA Cell Biol 2005; 24: 141–147
   PubMed Web of Science ®Google Scholar